REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
EQ Crusoea,b, GN Ribeiroc, FL Mourad, AC Netoe, M Aranhaf, RI Bittencourtg, EF Ribeiroh, JVP Netoi, A Maiolinoj,k, V Hungrial
a Universidade Federal da Bahia (UFBA), Salvador, Brazil
b Rede D'Or Oncologia, Brazil
c Clínica Hematológica, Brazil
d AC Camargo Câncer Center, São Paulo, Brazil
e Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil
f HemoMed, Instituto de Ensino e Pesquisa (IEP), São Paulo, Brazil
g Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
h Hospital Santa Lucia, Brazil
i Grupo Oncoclínicas Brasília, Brasília, Brazil
j Instituto Americas de Pesquisa, Ensino e Inovação, Brazil
k Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
l Clínica São Germano, São Paulo, Brazil
Ver másRead
685
Timeswas read the article
151
Total PDF
534
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 May | 47 | 15 | 62 |
| 2025 April | 70 | 6 | 76 |
| 2025 March | 100 | 14 | 114 |
| 2025 February | 90 | 17 | 107 |
| 2025 January | 87 | 25 | 112 |
| 2024 December | 57 | 16 | 73 |
| 2024 November | 59 | 36 | 95 |
| 2024 October | 24 | 22 | 46 |
